Opinion on the safety of orally ingested probiotics
There are currently no indications that the regular consumption of probiotics by healthy people involves risks. The outcome of the PROPATRIA project into the effect of probiotics in patients with pancreatitis is no reason to change this position. Vulnerable groups such as people with a seriously weakened immune system or severe intestinal disorders should exercise caution when using probiotics. The effects of probiotics in pregnant women and the long-term effects in infants are not sufficiently examined to judge the safety. Therefore, research into possible risks of the use of probiotics by ve... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | report |
Erscheinungsdatum: | 2009 |
Verlag/Hrsg.: |
Zenodo
|
Schlagwörter: | Opinion / risk assessment / probiotics / pregnant women / children / immune system / Netherlands |
Sprache: | unknown |
Permalink: | https://search.fid-benelux.de/Record/base-29218357 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.5281/zenodo.343906 |
There are currently no indications that the regular consumption of probiotics by healthy people involves risks. The outcome of the PROPATRIA project into the effect of probiotics in patients with pancreatitis is no reason to change this position. Vulnerable groups such as people with a seriously weakened immune system or severe intestinal disorders should exercise caution when using probiotics. The effects of probiotics in pregnant women and the long-term effects in infants are not sufficiently examined to judge the safety. Therefore, research into possible risks of the use of probiotics by very young children and pregnant women is necessary. The probiotic strains that are on the market usually have a ‘history of safe use’ and are not formally evaluated for safety. A safety assessment under the existing regulations is required for all new strains and known strains that are used as components of new products meant for consumption by vulnerable groups. ; NL; nl; vwaefsafocalpoint@vwa.nl